Ind-Swift Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ind-Swift Laboratories submitted its audited financial results for Q4 and FY ended March 31, 2025, on both standalone and consolidated basis. The scheme of amalgamation of Ind-Swift Limited with Ind-Swift Laboratories was sanctioned by NCLT on July 17, 2025 and became effective on August 8, 2025, resulting in recognition of a capital reserve of Rs. 46,588.29 lakhs under the pooling of interest method. Standalone revenue from operations fell to Rs. 54,964.67 lakhs (FY25) from Rs. 167,256.60 lakhs (FY24), while standalone profit after tax stood at Rs. 25,608.53 lakhs (FY25) vs Rs. 53,617.88 lakhs (FY24), partly boosted by exceptional income of Rs. 22,320.42 lakhs. The Board also approved allotment of 14,20,000 1% Redeemable Preference Shares of Rs. 100 each to eligible shareholders of the amalgamating company. Statutory auditor M/s Rattan Kaur & Associates issued an unmodified opinion with an emphasis of matter on the merger, warrant conversion, fixed deposit repayments, and asset sales at Baddi units.
The completed merger consolidates the two Ind-Swift group entities and substantially strengthened the balance sheet (equity rose to Rs. 1,16,407.81 lakhs from Rs. 79,814.89 lakhs, non-current borrowings dropped to Rs. 2,254.16 lakhs from Rs. 19,589.89 lakhs), but the steep YoY decline in revenue and negative operating cash flow of Rs. (3,915.39) lakhs warrant close monitoring of post-merger operational performance.